Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
March 18, 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
$135 Billion Immuno-Oncology Markets, 2024
January 07, 2021 08:13 ET
|
Research and Markets
Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Market, by Type (mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)), by Application (Lung,...
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET
|
Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
How To Prevent And Treat Common Summer Rashes; American Academy of Dermatology
August 11, 2020 14:30 ET
|
American Academy of Dermatology
ROSEMONT, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) -- As the coronavirus continues to spread throughout the country, many people may find themselves spending more time outdoors for a much-needed change...
BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombinationstherapie aus FixVac und Libtayo® (Cemiplimab) bekannt
July 31, 2020 02:00 ET
|
BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung einer randomisierten Phase-2-Studie mit einer Kombination aus FixVac BNT111 und Libtayo für die Behandlung von maligem Melanom (schwarzer...
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
July 31, 2020 02:00 ET
|
BioNTech SE
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockadeCombines two...
BioNTech veröffentlicht Daten aus Studie mit mRNA-basiertem FixVac-Melanom-Programm BNT111 in Nature
July 30, 2020 03:00 ET
|
BioNTech SE
Vorläufige Phase-1-Ergebnisse der Lipo-MERIT-Studie mit Daten von 89 Patienten zeigen vorteilhaftes Verträglichkeitsprofil für BNT111 in Patienten mit fortgeschrittenem malignem...
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
July 30, 2020 03:00 ET
|
BioNTech SE
Preliminary Phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in advanced melanoma patientsEfficacy analysis in a subset of 42...
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
July 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...